Another win for CogState
Tuesday, 12 August, 2008
CogState [ASX: CGS] has signed a contract worth $1.2 million which will see the company provide technology to a major pharmaceutical company for use in a Phase III schizophrenia study.
The cognition specialist company will be providing its computerised cognitive testing technology for the trial, which is to be conducted in over 70 sites.
This is the ninth contract the company has signed since July.
The nine contracts have a combined value of $2.3 million, and CogState is expecting that 63 per cent of the contracts' revenue will be earned in the coming financial year.
SEQ koala population carries immunity to retrovirus
Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...
RSV immunisation program for babies slashes hospital stays
An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...
A targeted treatment option for psoriasis
New research from MedUni Vienna paves the way for the development of a therapy that not only...
